From Yahoo Finance: 2025-05-20 09:13:00

ClearBridge Investments released its Q1 2025 investor letter, noting a -4.3% decline in the S&P 500 Index due to a tariff war and shift away from AI-related tech stocks. The strategy underperformed the benchmark in Q1, but the Russell 1000 Value Index outperformed its growth counterpart. Novo Nordisk A/S (NYSE:NVO) stocks were highlighted, with a one-month return of 11.87%.

In its investor letter, ClearBridge Large Cap Value Strategy discussed Novo Nordisk A/S (NYSE:NVO), a leader in diabetes care. Novo Nordisk A/S (NYSE:NVO) saw a 11.87% one-month return and shares lost 50.41% of their value in the last 52 weeks. On May 19, 2025, Novo Nordisk A/S (NYSE:NVO) stock closed at $67.02 per share with a market capitalization of $292.25 billion.

ClearBridge Large Cap Value Strategy initiated a new position in Novo Nordisk A/S (NYSE:NVO), citing the company’s strength in the GLP-1 diabetes and obesity drug market. They believe the market remains vast and Novo (alongside Eli Lilly) is well-positioned for growth. Novo Nordisk A/S (NYSE:NVO) was not among the 30 most popular stocks among hedge funds, but delivered 18% sales growth and 20% operating profit growth in Q1 2025.



Read more at Yahoo Finance: What Makes Novo Nordisk (NVO) a Lucrative Investment?